Denver Advanced Neurological Treatment Center
|

 

Contact Advanced Neurological Evaluation and Treatment Center of Denver ADVANCED NEUROLOGICAL EVALUATION AND TREATMENT CENTER
1721 East 19th Avenue, Suite 510, Denver, CO 80218

Contact Dr.Feldman's office Maps/Directions

Gaucher's Disease


What is Gaucher's Disease?

Gaucher disease is an inherited metabolic disorder in which harmful quantities of a fatty substance called glucocerebroside accumulate in the spleen, liver, lungs, bone marrow, and sometimes in the brain. There are three types of Gaucher disease. The first category, called type 1, is by far the most common. Symptoms may begin early in life or in adulthood. People in this group usually bruise easily due to low blood platelets and experience fatigue due to anemia They also have an enlarged liver and spleen, skeletal disorders, and, in some instances, lung and kidney impairment. There are no signs of brain involvement. Symptoms can appear at any age. In type 2 Gaucher disease, liver and spleen enlargement are apparent by 3 months of age. Individuals have extensive and progressive brain damage and usually die before 2 years of age. In the third category, called type 3, liver and spleen enlargement is variable, and signs of brain involvement such as seizures gradually become apparent. Major symptoms also include skeletal irregularities, eye movement disorders, and blood disorders. All Gaucher patients exhibit a deficiency of an enzyme called glucocerebrosidase that is involved in the breakdown and recycling of glucocerebroside. The buildup of this fatty material within cells prevents the cells and organs from functioning properly. Gaucher disease is one of several lipid storage diseases.

Is there any treatment?

Highly effective enzyme replacement therapy is available for most people with types 1 and 3 Gaucher disease. This therapy decreases liver and spleen size, reduces skeletal anomalies, and successfully reverses other symptoms of the disorder, including abnormal blood counts. Bone marrow transplantation (a procedure to replace damaged or destroyed blood-forming cells) can reverse the non-neurological effects of type 1 Gaucher disease, but it carries a high mortality rate due to imperfect donor matches. This procedure has been replaced by enzyme replacement therapy. There is no effective treatment for severe brain damage that may occur in persons with types 2 and 3 Gaucher disease.

What is the prognosis?

Enzyme replacement therapy is very beneficial for type 1 and most type 3 patients with this condition.

What research is being done?

The National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health), supports research to find ways to treat and prevent lipid storage disorders. This research includes clinical studies by the NINDS Developmental and Metabolic Neurology Branch.

 


Return to disorders index

 

Dr.Alexander Feldman, Denver NeurologistMeet Dr. Alexander Feldman and other specialists in Advanced Neurological Evaluation and Treatment Center of Denver.